An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection
about
The many ways to make a luminal cell and a prostate cancer cellKallikreins as biomarkers for prostate cancerProstate cancer: ESMO Consensus Conference Guidelines 2012Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer.Risk stratification of prostate cancer patients based on EPS-urine zinc contentJoint modelling of longitudinal and time-to-event data with application to predicting abdominal aortic aneurysm growth and ruptureProstate-specific antigen screening in prostate cancer: perspectives on the evidenceGleason 6 Prostate Cancer: Translating Biology into Population Health.Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer.Decision analysis of dutasteride use for patients with negative prostate biopsyMALDI-target integrated platform for affinity-captured protein digestionThe use of multiphase nonlinear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer.Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.Reconciling primary care and specialist perspectives on prostate cancer screening.Sixteen-year longitudinal changes in serum prostate-specific antigen levels: the olmsted county studyTemporal changes in the clinical approach to diagnosing prostate cancerDifferentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics.Should prostate-specific antigen velocity be abandoned?PSA velocity may not be of value in prostate cancer detection.Racial differences in longitudinal changes in serum prostate-specific antigen levels: the Olmsted County Study and the Flint Men's Health Study.Risk-based prostate cancer screening.The epigenetic promise for prostate cancer diagnosis.Testosterone replacement and prostate cancer.Informed prostate cancer risk-adjusted testing: a new paradigm.Risk stratification in prostate cancer screening.Risk-based prostate cancer screening: who and how?Prostate cancer: measuring PSA.Biomarkers in localized prostate cancer.Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.What's new in screening in 2015?Clarifying the PSA grey zone: The management of patients with a borderline PSA.An Analytical Study of Prostate-Specific Antigen DynamicsProstate-specific Antigen Density Variation Rate as a Potential Guideline Parameter for Second Prostate Cancer Detection Biopsy.Prostate-specific antigen (PSA) velocity: a test of controversial benefit in the era of increased prostate cancer screeningRisk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial.Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population.Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.Dynamic Prediction of Renal Failure Using Longitudinal Biomarkers in a Cohort Study of Chronic Kidney Disease.
P2860
Q26797386-2BC28C46-4987-4ECA-8ECB-EA1567CD227CQ26862434-E1A3EF1C-8C70-47A8-A314-10E98E451506Q27022847-42FE0E13-FDE8-4E39-9849-340EEDCF7A3CQ33745069-165749F7-4BC7-4A8A-82B5-5CB4685D1277Q33932686-BDE8161C-14A1-4712-8908-59173085C8F8Q33990605-3406E14C-42A9-4140-8A1C-5B8D36319604Q34354430-E596FD27-1F54-4174-B14F-B74AC290BEA1Q34470640-42E9244C-E30A-49A8-82B0-2CCB0A4A6BAEQ34536729-05108C94-2B25-4C12-A2B3-8729A4F0822CQ35020507-EFA7F8F1-C8E2-41BB-B614-549A97A27169Q35072160-50593621-9F20-4092-ADCD-F906F3814C02Q35854039-C7CCED9E-F9BB-4895-8881-2FE3977D9E71Q36033729-3CA4FB33-2037-438D-A7DF-24000934E7D9Q36145417-4C092B6E-DDEC-4E09-9109-5A9E154137A2Q36392498-93A11FB6-F34F-4E15-81EA-1878193F765CQ36512827-56497D7E-5426-496B-8925-3E1AE441BD93Q36520528-87F33B5A-333D-455F-BF05-88F5706EB59CQ37037804-A10A2A0F-B0C2-4A70-8D9D-669424B3989CQ37084685-70B83FEB-857F-45D9-8C9F-2F2E4CC8579AQ37085382-C072A600-2173-4D3F-AEA6-1D7EA546127BQ37496282-E8386763-C8E8-4451-9F2A-29D27B94FD0BQ37963657-8F07C69C-6866-480C-9AE8-DDC66B530EDFQ37967574-E6290679-4E94-4E50-8F5C-4F469B0DA013Q38037508-2B3DF6F6-2961-4072-9FB8-29E5090310B9Q38063556-178F9650-CB07-4F30-8003-CC7E30BBBC55Q38068114-332F1151-C32F-4318-8C80-12CA075E60C4Q38093463-CBF36768-C7C8-4E23-A107-E58AFDD1C89FQ38210857-19040CFA-BEEA-4510-A1AB-AB6EF708D4C4Q38697114-EE03DB48-8545-4C1E-8746-75CBD0A40A89Q38774550-892ABEA1-9A43-4E58-AA1D-B88AD48D3C2DQ38789947-1848DE0E-813C-4CDF-9531-887A9D74F436Q38871819-19B5400D-73D7-47A4-A42E-D32888CEFDC7Q38965360-4D0EC099-14C9-494D-9B46-B37EA01398C5Q39106951-47FC9B6A-22E0-42A6-89F2-326F1224F119Q39564842-833F9DA4-8F3C-4439-9F27-A95F5C8074CAQ41833638-F5080248-A974-4812-BD63-A7D801170CF3Q43431647-444C0E57-86FD-4AF6-8B4E-94461EDBE000Q46022495-5931032C-82F5-4E26-8C11-90B96E31D5E5Q46853931-72F5B399-902A-4F86-8C42-9D132BEA152BQ47294204-E68760BD-BB0F-4F65-A8DF-39204AC5B0DF
P2860
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
An empirical evaluation of gui ...... y in prostate cancer detection
@ast
An empirical evaluation of gui ...... y in prostate cancer detection
@en
An empirical evaluation of gui ...... y in prostate cancer detection
@nl
type
label
An empirical evaluation of gui ...... y in prostate cancer detection
@ast
An empirical evaluation of gui ...... y in prostate cancer detection
@en
An empirical evaluation of gui ...... y in prostate cancer detection
@nl
prefLabel
An empirical evaluation of gui ...... y in prostate cancer detection
@ast
An empirical evaluation of gui ...... y in prostate cancer detection
@en
An empirical evaluation of gui ...... y in prostate cancer detection
@nl
P2093
P2860
P356
P1476
An empirical evaluation of gui ...... y in prostate cancer detection
@en
P2093
Cathee Till
Catherine M Tangen
Ian M Thompson
P2860
P304
P356
10.1093/JNCI/DJR028
P407
P577
2011-02-24T00:00:00Z